Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Tolerability of Neoadjuvant Nivolumab for Locally Advanced Resectable Oral Cancer Combined With [18F] BMS-986192 / [18F] -FDG PET Imaging and Immunomonitoring for Response Prediction

Next Previous
Trial Profile

Safety and Tolerability of Neoadjuvant Nivolumab for Locally Advanced Resectable Oral Cancer Combined With [18F] BMS-986192 / [18F] -FDG PET Imaging and Immunomonitoring for Response Prediction

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 04 Oct 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary) ; BMS 986192; Fludeoxyglucose F-18
  • Indications Mouth neoplasm; Squamous cell cancer
  • Focus Adverse reactions; Pharmacogenomic
  • Acronyms NeoNivo

Most Recent Events

  • 30 Apr 2023 Status changed from active, no longer recruiting to completed.
  • 06 Oct 2021 Planned End Date changed from 1 Apr 2022 to 31 Aug 2022.
  • 06 Oct 2021 Planned primary completion date changed from 1 Apr 2021 to 30 Nov 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top